肿瘤药学2018，Vol.8Issue(1)：124-128,5.DOI:10.3969/j.issn.2095-1264.2018.01.29
5例浆母细胞淋巴瘤临床病例分析和文献回顾
Case Report on 5 Plasmablastic Lymphoma Patients and Literature Review by Retrospective Analysis
范舟 1李基炜 1易平勇 1李昆仑 1李津 1周倩倩 1刘先领2
作者信息
- 1. 湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院,湖南 长沙,410013
- 2. 中南大学湘雅二医院,湖南 长沙,410006
- 折叠
摘要
Abstract
Objective To investigate the clinical and pathologic feature, immunophenotype, treatment and prognosis of plasmablastic lymphoma patients. Methods The clinical data of 5 plasmablastic lymphoma patients who were admitted into the Second Xiangya Hospital of Central South University and Hunan Cancer Hospital between 2010 and 2016 was collected. We analyzed the clinical and pathologic fea-tures, immunophenotype, treatment and prognosis of these five cases, followed by a review of related literature in China and abroad. Results A1l of these 5 patients were diagnosed as HIV-negative PBL, 4 of 5 patients were males, and only one was female. The median age was 53.8(42~66) years old. Four had B symptoms. All the 5 patients showed the morphologicalfeature of immunoblasts but plasma cell immu-nophenotype. Three patients received a thracycline based chemotherapy, two patients received bortezomib. One patient received GEMOX (Gemcitabine, Oxaliplatin) and involved field radiotherapy. Only one patient underwent right hemicolectomy. Three patients achieved dura-ble complete response and are still alive with survival times of 24, 10, 23 months respectively. Two patients had progressive disease and died 3 and 6 months after admission. Conclusion We conclude that plasmablastic lymphoma is a rare lymphoma which resembles immunoblasts morphologically but showed plasma cell immunophenotype, and this tumor progress rapidly clinically and have poor prognosis, the treatment remains a challenge, more effective treatment regimen is urged to be investigated.关键词
浆母细胞淋巴瘤/化疗/预后/病理Key words
Plasmablastic lymphoma/Chemotherapy/Prognosis/Pathology分类
医药卫生引用本文复制引用
范舟,李基炜,易平勇,李昆仑,李津,周倩倩,刘先领..5例浆母细胞淋巴瘤临床病例分析和文献回顾[J].肿瘤药学,2018,8(1):124-128,5.
